Table 2 Summary of nivolumab trials in malignant cancer
From: Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies
Pathology | Trial | Phase | No of. patients | Treatment | mPFS (months) | mOS (months) | ORR (%) | Other outcomes |
|---|---|---|---|---|---|---|---|---|
Melanoma | CheckMate-037 | III | 370 | Nivolumab vs. ICC | – | – | 31.7 vs. 10.6 | – |
|  | CheckMate-067 | III | 945 | Nivolumab + ipilimumab vs. Monotherapy (Ipilimumab or Nivolumab) | 11.5 vs. 6.9 vs. 2.9 | – | 50 vs. 40 vs. 14 | – |
NSCLC | CheckMate-017 | III | 272 | Nivolumab vs. Docetaxel | – | 9.2 vs. 6.0 |  | – |
HNSCC | CheckMate-141 | III | 361 | Nivolumab vs. ICC | – | 7.5 vs. 5.1 | 13.3 vs. 5.8 | – |
UC | CheckMate-275 | II | 270 | Nivolumab | 2.0 | – | 19.6 | – |
cHL | CheckMate-205 | II | 243 | Nivolumab | 14.7 | – | 69 | CR: 16%; DOR: 16.6 months |
FL | Lesokhin et al | Ib | – | Nivolumab | – | – | 40 | – |
DLBCL | Cao et al | – | 11 | Nivolumab + Anti-CD19 CAR-T cell therapy | – | – | 81.81 | CR: 45.45% |
AML | Daver et al | II | 70 | Nivolumab + Azacitidine vs. Demethylation medication | – | 6.3 vs. 4.6 | 33 vs. 20 | CR: 8%; PR: 19% |
CLL | Jain et al | II | – | Nivolumab + Ibrutinib | – | – | 43 | – |
Ovarian cancer | Hamanishi et al | II | 20 | Nivolumab | 3.5 | 20.0 | 15 | DCR: 45% |
RCC | CheckMate-214 | III | 847 | Nivolumab + Ipilimumab vs. Sunitinib | 11.6 vs. 8.4 | 75%* vs. 60%* | 42 vs. 27 | CR: 9% vs. 1% |